FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013153485> ?p ?o ?g. }

• W3013153485 endingPage "646" @default.
• W3013153485 startingPage "636" @default.
• W3013153485 abstract "Objective To evaluate long-term safety/tolerability of brivaracetam at individualized doses ≤200 mg/d (primary) and maintenance of efficacy over time (secondary) in adults with focal seizures or primary generalized seizures (PGS) enrolled in phase 3, open-label, long-term follow-up trial N01199 (NCT00150800). Methods Patients ≥16 years of age who had completed double-blind, placebo-controlled adjunctive brivaracetam trials NCT00175825, NCT00490035, NCT00464269, or NCT00504881 were eligible. Outcomes included safety, efficacy, and quality of life. Results The safety set included 667 patients (focal seizures, 97.8%; PGS, 2.2%); the efficacy set included 648 patients with focal seizures and 15 patients with PGS. Overall, 49.2% of patients had ≥48 months of exposure. Treatment-emergent adverse events (TEAEs) occurred in 91.2% of all patients (91.3% of focal seizures group), brivaracetam discontinuation due to TEAEs in 14.8%, drug-related TEAEs in 56.7%, and serious TEAEs in 22.8%. The most common TEAEs in the focal seizures group (≥15%) were headache (25.3%) and dizziness (21.9%). Mean changes from baseline in Hospital Anxiety and Depression Scale scores at last value during 2-year evaluation were −0.7 (standard deviation [SD] = 4.3) and −0.2 (SD = 4.4) overall. In the focal seizures group, median reduction from baseline in focal seizure frequency/28 days was 57.3%, 50% responder rate was 55.6%, and 6-month and 12-month seizure freedom rates were 30.3% and 20.3%, respectively. Efficacy outcomes improved by exposure duration cohort and then stabilized through the 108-month cohort. Mean improvement from baseline in Patient-Weighted Quality of Life in Epilepsy Inventory total score (efficacy set) was 5.7 (SD = 16.1, Cohen's d = 0.35) at month 12 and 6.5 (SD = 18.0, Cohen's d = 0.36) at month 24. Significance Adjunctive brivaracetam was well tolerated, with a good safety profile in long-term use in adults with epilepsy at individualized doses. Approximately half of the patients remained in the trial at 4 years. Brivaracetam reduced focal seizure frequency versus baseline. Efficacy improved with increasing exposure duration and remained stable through the 9-year cohort." @default.
• W3013153485 created "2020-04-03" @default.
• W3013153485 creator A5002976712 @default.
• W3013153485 creator A5011328614 @default.
• W3013153485 creator A5012309923 @default.
• W3013153485 creator A5079459105 @default.
• W3013153485 creator A5079889841 @default.
• W3013153485 creator A5085356343 @default.
• W3013153485 date "2020-03-28" @default.
• W3013153485 modified "2023-10-11" @default.
• W3013153485 title "Long‐term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11‐year, open‐label, follow‐up trial" @default.
• W3013153485 cites W1502126985 @default.
• W3013153485 cites W1572262481 @default.
• W3013153485 cites W1845447069 @default.
• W3013153485 cites W1916788136 @default.
• W3013153485 cites W1981401201 @default.
• W3013153485 cites W1990601331 @default.
• W3013153485 cites W1992028227 @default.
• W3013153485 cites W1993852409 @default.
• W3013153485 cites W1995505488 @default.
• W3013153485 cites W2011926671 @default.
• W3013153485 cites W2021074267 @default.
• W3013153485 cites W2023205599 @default.
• W3013153485 cites W2051013481 @default.
• W3013153485 cites W2065301637 @default.
• W3013153485 cites W2099690974 @default.
• W3013153485 cites W2134247911 @default.
• W3013153485 cites W2148083007 @default.
• W3013153485 cites W2166281097 @default.
• W3013153485 cites W2419659369 @default.
• W3013153485 cites W2565520871 @default.
• W3013153485 cites W2590850394 @default.
• W3013153485 cites W2594644573 @default.
• W3013153485 cites W2762538576 @default.
• W3013153485 cites W3013153485 @default.
• W3013153485 cites W4236676256 @default.
• W3013153485 doi "https://doi.org/10.1111/epi.16484" @default.
• W3013153485 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7384045" @default.
• W3013153485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32221987" @default.
• W3013153485 hasPublicationYear "2020" @default.
• W3013153485 type Work @default.
• W3013153485 sameAs 3013153485 @default.
• W3013153485 citedByCount "17" @default.
• W3013153485 countsByYear W30131534852020 @default.
• W3013153485 countsByYear W30131534852021 @default.
• W3013153485 countsByYear W30131534852022 @default.
• W3013153485 countsByYear W30131534852023 @default.
• W3013153485 crossrefType "journal-article" @default.
• W3013153485 hasAuthorship W3013153485A5002976712 @default.
• W3013153485 hasAuthorship W3013153485A5011328614 @default.
• W3013153485 hasAuthorship W3013153485A5012309923 @default.
• W3013153485 hasAuthorship W3013153485A5079459105 @default.
• W3013153485 hasAuthorship W3013153485A5079889841 @default.
• W3013153485 hasAuthorship W3013153485A5085356343 @default.
• W3013153485 hasBestOaLocation W30131534851 @default.
• W3013153485 hasConcept C118552586 @default.
• W3013153485 hasConcept C126322002 @default.
• W3013153485 hasConcept C187212893 @default.
• W3013153485 hasConcept C197934379 @default.
• W3013153485 hasConcept C2778186239 @default.
• W3013153485 hasConcept C2778375690 @default.
• W3013153485 hasConcept C2778715236 @default.
• W3013153485 hasConcept C3018162438 @default.
• W3013153485 hasConcept C42219234 @default.
• W3013153485 hasConcept C71924100 @default.
• W3013153485 hasConceptScore W3013153485C118552586 @default.
• W3013153485 hasConceptScore W3013153485C126322002 @default.
• W3013153485 hasConceptScore W3013153485C187212893 @default.
• W3013153485 hasConceptScore W3013153485C197934379 @default.
• W3013153485 hasConceptScore W3013153485C2778186239 @default.
• W3013153485 hasConceptScore W3013153485C2778375690 @default.
• W3013153485 hasConceptScore W3013153485C2778715236 @default.
• W3013153485 hasConceptScore W3013153485C3018162438 @default.
• W3013153485 hasConceptScore W3013153485C42219234 @default.
• W3013153485 hasConceptScore W3013153485C71924100 @default.
• W3013153485 hasFunder F4320337846 @default.
• W3013153485 hasIssue "4" @default.
• W3013153485 hasLocation W30131534851 @default.
• W3013153485 hasLocation W30131534852 @default.
• W3013153485 hasLocation W30131534853 @default.
• W3013153485 hasLocation W30131534854 @default.
• W3013153485 hasLocation W30131534855 @default.
• W3013153485 hasOpenAccess W3013153485 @default.
• W3013153485 hasPrimaryLocation W30131534851 @default.
• W3013153485 hasRelatedWork W2085418720 @default.
• W3013153485 hasRelatedWork W2792428998 @default.
• W3013153485 hasRelatedWork W2793900558 @default.
• W3013153485 hasRelatedWork W2803956198 @default.
• W3013153485 hasRelatedWork W2888797318 @default.
• W3013153485 hasRelatedWork W2905824751 @default.
• W3013153485 hasRelatedWork W3000507271 @default.
• W3013153485 hasRelatedWork W4285406639 @default.
• W3013153485 hasRelatedWork W4376129482 @default.
• W3013153485 hasRelatedWork W8168635 @default.
• W3013153485 hasVolume "61" @default.
• W3013153485 isParatext "false" @default.
• W3013153485 isRetracted "false" @default.
• W3013153485 magId "3013153485" @default.

• next